These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

969 related items for PubMed ID: 27154182

  • 1. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T, Diamond TH, Manoharan A, Ramakrishna R.
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T, Diamond TH, Manoharan A, Ramakrishna R.
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E.
    J Clin Oncol; 2002 Mar 15; 20(6):1625-34. PubMed ID: 11896113
    [Abstract] [Full Text] [Related]

  • 4. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G.
    Leukemia; 2020 Dec 15; 34(12):3111-3125. PubMed ID: 33046818
    [Abstract] [Full Text] [Related]

  • 5. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV, Landgren O.
    Cancer Treat Res; 2016 Dec 15; 169():3-12. PubMed ID: 27696254
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical characteristics and outcomes in biclonal gammopathies.
    Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK.
    Am J Hematol; 2016 May 15; 91(5):473-5. PubMed ID: 26840395
    [Abstract] [Full Text] [Related]

  • 10. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
    Dong L, Chen CY, Ning B, Xu DL, Gao JH, Wang LL, Yan SY, Cheng S.
    Genet Mol Res; 2015 Aug 14; 14(3):9571-84. PubMed ID: 26345890
    [Abstract] [Full Text] [Related]

  • 11. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A, Moore S, Crowe J, Murray J, Peacock O, Thompson D, Betts F, Rapps S, Ross L, Rothschild-Rodriguez D, Arana Echarri A, Davies R, Lewis R, Augustine DX, Whiteway A, Afzal Z, Heaney J, Drayson MT, Turner JE, Campbell JP.
    BMC Cancer; 2024 Feb 05; 24(1):174. PubMed ID: 38317104
    [Abstract] [Full Text] [Related]

  • 12. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.
    Int J Lab Hematol; 2016 May 05; 38 Suppl 1():110-22. PubMed ID: 27161311
    [Abstract] [Full Text] [Related]

  • 13. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
    Landgren O, Rajkumar SV.
    Semin Hematol; 2011 Jan 05; 48(1):66-72. PubMed ID: 21232660
    [Abstract] [Full Text] [Related]

  • 14. Regression of Intermediate-High Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) With Long-term Use of Curcumin: A Case Report.
    Golombick T, Ramakrishna R, Manoharan A.
    Integr Cancer Ther; 2024 Jan 05; 23():15347354241242099. PubMed ID: 38529782
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B, Edwards CM.
    Curr Osteoporos Rep; 2018 Dec 05; 16(6):635-641. PubMed ID: 30229522
    [Abstract] [Full Text] [Related]

  • 17. B-Cell Disorders and Curcumin.
    Golombick T, Diamond TH, Manoharan A, Ramakrishna R.
    Integr Cancer Ther; 2017 Sep 05; 16(3):255-257. PubMed ID: 26674787
    [Abstract] [Full Text] [Related]

  • 18. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V, Mateos MV.
    Eur J Intern Med; 2018 Dec 05; 58():57-63. PubMed ID: 29907380
    [Abstract] [Full Text] [Related]

  • 19. [Smoldering multiple myeloma].
    Fouquet G, Guidez S, Herbaux C, Demarquette H, Leleu X.
    Rev Med Interne; 2014 Apr 05; 35(4):243-9. PubMed ID: 24050785
    [Abstract] [Full Text] [Related]

  • 20. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY.
    Ann Intern Med; 2024 Apr 05; 177(4):449-457. PubMed ID: 38560901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.